⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MYGN News
Myriad Genetics Inc
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
globenewswire.com
MYGN
Diality Appoints Peter Donato as Chief Financial Officer
businesswire.com
TFX
STIM
MYGN
Form 8-K
sec.gov
MYGN
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
globenewswire.com
MYGN
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
globenewswire.com
MYGN
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
globenewswire.com
MYGN
Immunoassay Research Report 2026: Market Strategies, Trends and Forecasts 2025-2029 by Application, Technology, Product, User and Country With Executive Guides, Impact of Artificial Intelligence
globenewswire.com
ABT
BIIB
BDX
BIO
EXAS
ISRG
LH
MYGN
ORCL
PDX
QDEL
REGN
TMO
XRAY
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
globenewswire.com
MYGN
Truveta deepens oncology and scientific leadership with appointment of Johnathan Lancaster, MD, PhD as President and Chief Scientific Officer
globenewswire.com
REGN
MYGN
SelfDecode Powers DNA Traits Experience for MyHeritage Customers Worldwide
prnewswire.com
MYGN